SEC16B

Across TCGA pan-cancer cohorts, SEC16B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SEC16B data layer compared with 19 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SEC16B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SEC16B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

STAD, CESC, and UCEC are the cancer types where SEC16B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
CESC	OS	Median	III,IV	0.091	0.755	<.001	34	view →
UCEC	DFS	Median	All	0.828	0.628	.006	22	view →
READ	DFS	Median	II,III,IV	0.431	0.805	.010	12	view →
LIHC	DFS	Median	All	0.102	0.555	.003	12	view →
PRAD	DFS	Median	All	0.448	0.888	<.001	8	view →
LUAD	OS	Median	All	0.361	0.701	.020	6	view →
SKCM	OS	Median	II,III,IV	0.957	0.720	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SEC16B–STAD (OS)

Open the STAD breakdown →